Molecular Characteristics of IS1216 Carrying Multidrug Resistance Gene Cluster in Serotype III/Sequence Type 19 Group B Streptococcus

Yong Zhi, a,b Hyun Jung Ji, a,c Jong Hyun Jung, a,b Eui Baek Byun, a Woo Sik Kim, a,d Shun Mei Lin, a Sangyong Lim, a,b A-Yeung Jang, a Min Joo Choi, a,b Ki Bum Ahn, a Jae Hyang Lim, a,d Joon Young Song, a e Ho Seong Seo a,b

a Research Division for Biotechnology, Korea Atomic Energy Research Institute, Jeongeup, Republic of Korea
b Department of Radiation Science, University of Science and Technology, Daejeon, Republic of Korea
c Department of Oral Microbiology and Immunology, DRI, and BK21 Plus Program, School of Dentistry, Seoul National University, Seoul, Republic of Korea
d Functional Biomaterial Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Republic of Korea
e Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
f Department of Microbiology, Ewha Womans University College of Medicine, Seoul, Republic of Korea
g Ewha Education & Research Center for Infection, Ewha Womans University Medical Center, Seoul, Republic of Korea
h Department of Radiation Science, University of Science and Technology, Daejeon, Republic of Korea

ABSTRACT  Strepotococcus agalactiae is the leading cause of meningitis in newborns and a significant cause of invasive diseases in pregnant women and adults with underlying diseases. Antibiotic resistance against erythromycin and clindamycin in group B streptococcus (GBS) isolates has been increasing worldwide. GBS expresses the Srr1 and Srr2 proteins, which have important roles in bacterial infection. They have been investigated as novel vaccine candidates against GBS infection, with promising results. But a recent study detected non-srr1/2-expressing clinical isolates belonging to serotype III. Thus, we aimed to analyze the genotypes of non-srr1/2 GBS clinical isolates collected between 2013 and 2016 in South Korea. Forty-one (13.4%) of the 305 serotype III isolates were identified as non-srr1/2 strains, including sequence type 19 (ST19) (n = 16) and ST27 (n = 18) strains. The results of the comparative genomic analysis of the ST19/serotype III/non-srr1/2 strains further revealed four unique gene clusters. Site 4 in the srr1 gene locus was replaced by an IsaE(InhB(aaadK-aph-ada))-carrying multidrug-resistant gene cluster flanked by two IS1216 transposases with 99% homology to the enterococcal plasmid pKUB3007-1. Despite the Srr1 and Srr2 deficiencies, which resulted in reduced fibrinogen binding, the adherence of non-srr1/2 strains to endothelial and epithelial cells was comparable to that of Srr1- or Srr2-expressing strains. Moreover, their virulence in mouse models of meningitis was not significantly affected. Furthermore, additional adhesin-encoding genes, including a gene encoding a BspA-like protein, which may contribute to colonization by non-srr1/2 strains, were identified via whole-genome analysis. Thus, our study provides important findings that can aid in the development of vaccines and antibiotics against GBS.

IMPORTANCE Most previously isolated group B streptococcus (GBS) strains express either the Srr1 or Srr2 glycoprotein, which plays an important role in bacterial colonization and invasion. These glycoproteins are potential protein vaccine candidates. In this study, we first report GBS clinical isolates in which the srr1/2 gene was deleted or replaced with foreign genes. Despite Srr1/2 deficiency, in vitro adherence to mammalian cells and in vivo virulence in murine models were not affected, suggesting that the isolates might have another adherence mechanism that enhanced their virulence aside from Srr1/2-fibrinogen-mediated adherence. In addition, several non-srr1/2 isolates replaced the srr1/2 gene with the InhB and IsaE antibiotic resistance gene with the IS1216 transposases with 99% homology to the enterococcal plasmid pKUB3007-1. Despite the Srr1 and Srr2 deficiencies, which resulted in reduced fibrinogen binding, the adherence of non-srr1/2 strains to endothelial and epithelial cells was comparable to that of Srr1- or Srr2-expressing strains. Moreover, their virulence in mouse models of meningitis was not significantly affected. Furthermore, additional adhesin-encoding genes, including a gene encoding a BspA-like protein, which may contribute to colonization by non-srr1/2 strains, were identified via whole-genome analysis. Thus, our study provides important findings that can aid in the development of vaccines and antibiotics against GBS.
Streptococcus agalactiae (group B streptococcus [GBS]) is a Gram-positive commensal bacterium that colonizes the gastrointestinal, urinary, and genital tracts of healthy adults (1). Maternal GBS colonization is the leading cause of neonatal sepsis and meningitis and a significant cause of morbidity in immunocompromised adults, particularly the elderly (2, 3). Recent studies have reported that invasive GBS infections among the elderly were responsible for approximately 25 deaths/100,000 population in the United States in 2015 (4). The capsular polysaccharide (CPS), a major determinant in the categorization of GBS strains into 10 serotypes (Ia, Ib, and II to IX), is the most important virulence factor (5). However, several reports have described multilocus sequence typing (MLST) as another potential GBS classification system for describing the evolutionary relationships and epidemiology of prevalent sequence type (ST) isolates (6, 7). Using MLST, ST17 serotype III GBS strains, which currently account for the highest proportion of infant invasive disease, have been predicted as emerging highly virulent strains (8–11).

Penicillin G and ampicillin are the most widely used antibiotics for the prevention and treatment of GBS infections (12, 13); however, penicillin-nonsusceptible GBS isolates have been reported worldwide (14, 15). Meanwhile, erythromycin and clindamycin represent second-line antibiotics that are often recommended by the Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG) for patients with allergies to β-lactam antibiotics (16).

In addition, owing to their synergistic activity, aminoglycosides are commonly prescribed in combination with β-lactam antibiotics for streptococcal endocarditis (17) and prosthetic joint infections (18). However, the increasing resistance rates reported in South Korea (51.8%), China (74.1%), and other countries against macrolide and aminoglycoside antibiotics pose a serious global clinical challenge (19, 20).

GBS can also develop resistance to multiple antimicrobial compounds due to the acquisition of resistance genes hosted on mobile genetic elements (MGEs) (21). MGEs comprise insertion sequences (ISs), transposons (Tns), plasmids, and bacteriophages (22), which can translocate within, or between, prokaryotic genomes. Many MGEs have a significant role in facilitating horizontal genetic transfer (HGT) and promoting the acquisition of antibiotic resistance genes (23). In fact, in GBS, in which lincosamide-resistant strains are rarely isolated, the emergence of clinical isolates resistant to lincosamides is increasing due to the acquisition of an Inu(B)-carrying fragment (24–29). For instance, the GBS isolate SGB76 harbors a 12,076-bp Inu(B)-carrying fragment along with other antibiotic resistance genes, including aadE (streptomycin resistance), spw (spectinomycin resistance), and Isa(E) (pleuromutilin, lincosamide, and streptogramin A resistance). These genes are located between two IS1216 fragments that share a high degree of homology with the IS1216 locus located in Staphylococcus aureus SA7037 and Enterococcus faecalis pEF418 (30, 31). Moreover, the GBS strain UCN70, isolated from a vaginal swab, was reported to be macrolide, lincosamide, and streptogramin A resistant (32). Indeed, the expansion of MGEs containing antibiotic resistance genes in GBS has been suggested to contribute to the emergence of adult infections in non-pregnant individuals (33–40).

Clinical GBS isolates encode serine-rich-repeat (SRR) glycoproteins (Srr1 or Srr2), important adhesion molecules that interact with human fibrinogen (41, 42). Based on their significant roles in the pathogenesis of GBS infections, Srr1 and Srr2 have been investigated as attractive novel vaccine candidates against GBS infections. However, we previously reported that 3.2% (n = 6) of 185 GBS clinical isolates, collected at the Korea University Hospital (Seoul, South Korea), did not carry srr1 or srr2, and all belonged to serotype III (43). These findings prompted us to further investigate the
correlation between non-srr1/2 strains and GBS serotypes as well as the genomic characteristics associated with srr1/2 deficiency in GBS clinical isolates. Therefore, in the current study, 41 non-srr1/2 strains from 305 serotype III clinical isolates were analyzed using comparative whole-genome sequencing to investigate the relationship between their genetic structures and antibiotic resistance and virulence.

**RESULTS**

**Epidemiological analysis of non-srr1/2 GBS clinical isolates.** A total of 1,248 GBS clinical isolates were collected between 2013 and 2016 at the Korea University Guro Hospital (Seoul, South Korea). Capsular serotypes of the isolates were identified using a latex agglutination assay and multiplex PCR analysis, revealing 86 serotype Ia, 205 serotype Ib, 30 serotype II, 305 serotype III, 11 serotype IV, 124 serotype V, 99 serotype VI, 2 serotype VII, 185 serotype VIII, and 9 serotype IX isolates (Table 1). Additionally, 192 isolates were identified as nontypeable or multitypeable strains. Consistent with our previous report (43), serotype III (24.4%) represented the predominant GBS serotype. Interestingly, serotype VIII was also found to represent a major serotype isolated from the Korea University Guro Hospital, accounting for 14.8% of the clinical isolates and increasing from 7.0% in 2013 to 19.0% in 2016 during this study period.

We had previously determined that all non-srr1/2 strains were of serotype III (43), in the current study, we investigated the presence of the srr1 and srr2 genes in 305 serotype III isolates using a multiplex PCR assay. Among these isolates, 240 and 24 carried srr1 and srr2, respectively (Table 2). Notably, the remaining 41 isolates were identified as non-srr1/2 strains, accounting for 13.4% of serotype III and 3.3% of the total isolates. To further investigate the genetic characteristics of these strains, MLSTs and clonal complexes (CCs) of all 41 non-srr1/2 isolates were analyzed. Among the 41 non-srr1/2 isolates, 16 belonged to ST19, while the remaining 25 were of ST27 (n = 18), ST529 (n = 6), and ST171 (n = 1) (Table 3). eBURST analysis further revealed that all non-srr1/2 isolates, with the exception of one isolate (NSP14-65 [ST171; CC17]), belonged to CC19 (44). Taken together, 41 isolates (13.4%) of the 305 serotype III isolates were identified as non-srr1/2 strains, with the largest proportion belonging to CC19 (97.6%; n = 40).

**Phenotypic characteristics of non-srr1/2 isolates.** Generally, GBS strains express one of the two SRR proteins Srr1 and Srr2, which are heavily glycosylated cell wall-anchoring proteins (45–47). Thus, the loss of srr1 and srr2 expression in S9968 (ST19) and NSP15-73 (ST27) was confirmed by lectin blot analysis. The results show that a

---

**TABLE 1** Capsular serotypes of GBS clinical isolates

| Yr     | Ia (%) | Ib (%) | II (%) | III (%) | IV (%) | V (%) | VI (%) | VII (%) | VIII (%) | IX (%) | NT (%) | Total (%) |
|--------|--------|--------|--------|---------|--------|-------|--------|---------|----------|--------|---------|-----------|
| 2013   | 16 (8.6)| 32 (17.3)| 6 (3.2)| 41 (22.2)| 2 (1.1)| 20 (10.8)| 16 (8.6)| 0 (0.0)| 13 (7.0)| 1 (0.5)| 38 (20.5)| 185 (100) |
| 2014   | 12 (4.2)| 50 (17.4)| 4 (1.4)| 83 (28.9)| 2 (0.7)| 29 (10.1)| 28 (9.8)| 1 (0.3)| 24 (8.4)| 2 (0.7)| 52 (18.1)| 287 (100) |
| 2015   | 29 (7.7)| 63 (16.8)| 11 (2.9)| 97 (25.9)| 3 (0.8)| 31 (8.3)| 28 (7.5)| 1 (0.3)| 72 (19.2)| 0 (0.0)| 40 (10.7)| 375 (100) |
| 2016   | 29 (7.2)| 60 (15.0)| 9 (2.2)| 84 (20.9)| 4 (1.0)| 44 (11.0)| 27 (6.7)| 0 (0.0)| 76 (19.0)| 6 (1.5)| 62 (15.5)| 401 (100) |
| Total  | 86 (6.9)| 205 (16.4)| 30 (2.4)| 305 (24.4)| 11 (0.9)| 124 (9.9)| 99 (7.9)| 2 (0.2)| 185 (14.8)| 9 (0.7)| 192 (15.4)| 1,248 (100) |

**TABLE 2** Prevalence of srr genotypes in serotype III isolates from 2013 to 2016

| Genotype | No. of isolates from yr | Total no. (%) of isolates |
|----------|------------------------|---------------------------|
| srr1     | 29 66 78 67           | 240 (78.7)                |
| srr2     | 0 4 10 10             | 24 (7.9)                  |
| Non-srr1/2| 12 13 9 7        | 41 (13.4)                 |
| Total    | 41 83 97 84         | 305 (100.0)               |
A strong glycosylated protein signal was detected in the NEM316 strain, which was lost in the isogenic srr1 deletion mutant NEM316 (Δsrr1) (Fig. 1A). A strong glycosylated protein signal was also detected in the COH1 strain, which was lost upon srr2 deletion (Δsrr2). In contrast, no glycosylated protein signals were observed in the non-srr1/2 isolates S9968 and NSP15-73, suggesting the absence of Srr1/2 proteins in the non-srr1/2 strain serotype III GBS isolates. This was confirmed following our examination of an additional five non-srr1/2 strains, all of which lacked Srr1/2 protein expression (data not shown).

Considering the reported contribution of Srr1 or Srr2 to the colonization and virulence of GBS in the pathogenesis of meningitis and endocarditis via its interaction with human fibrinogen (48), we next sought to investigate the impact of srr1/2 gene loss in non-srr1/2 isolates on their fibrinogen binding activity. This activity was observed to be significantly reduced in the srr1- and srr2-deficient strains compared to that in their

### TABLE 3 STs, clonal complexes, and MICs of 41 non-srr1/2 isolates

| Isolate | ST | CC  | AMK | GEN | KAN | SPT | STR | TOB | CLI | LIN |
|---------|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| S9968   | 19 | 19  | 128 | 512 | 512 | 512 | 64  | 512 | 64  | 32  |
| S10039  | 19 | 19  | 128 | 512 | 512 | 512 | 64  | 512 | 64  | 128 |
| S10124  | 19 | 19  | 128 | 512 | 512 | 256 | 512 | 64  | 128 | 256 |
| S10171  | 19 | 19  | 128 | 512 | 512 | 256 | 512 | 64  | 32  | 32  |
| NSP14-81| 19 | 19  | 128 | 512 | 512 | 256 | 512 | 64  | 128 | 128 |
| NSP14-151| 19 | 19 | 128 | 512 | 512 | 32  | 64  | 512 | 128 | 256 |
| NSP14-167| 19 | 19 | 128 | 512 | 512 | 128 | 64  | 512 | 64  | 128 |
| NSP15-560| 19 | 19 | 128 | 512 | 512 | 512 | 64  | 512 | 64  | 128 |
| NSP15-613| 19 | 19 | 128 | 512 | 512 | 32  | 64  | 512 | 64  | 128 |
| NSP15-613| 19 | 19 | 128 | 512 | 512 | 32  | 64  | 512 | 64  | 128 |
| S9928   | 19 | 19  | 8   | 64  | 16  | 32  | 16  | 16  | 0.5 | 0.5 |
| NSP14-66| 19 | 19  | 4   | 32  | 32  | 16  | 8   | 0.5 | 0.5 | 0.5 |
| NSP14-659| 19 | 19 | 64  | 16  | 128 | 32  | 64  | 16  | 0.5 | 0.5 |
| NSP16-31| 19 | 19  | 64  | 8   | 64  | 32  | 64  | 16  | 0.5 | 0.5 |
| GBS16-54| 19 | 19  | 64  | 8   | 64  | 32  | 64  | 16  | 0.5 | 0.5 |
| S9981   | 27 | 19  | 128 | 64  | 16  | 32  | 16  | 16  | 0.5 | 0.5 |
| S10048  | 27 | 19  | 128 | 64  | 16  | 32  | 16  | 16  | 0.5 | 0.5 |
| S10072  | 27 | 19  | 128 | 64  | 32  | 64  | 16  | 0.5 | 0.5 | 0.5 |
| S10121  | 27 | 19  | 128 | 64  | 32  | 64  | 16  | 0.5 | 0.5 | 0.5 |
| NSP14-76| 27 | 19  | 128 | 64  | 32  | 64  | 16  | 0.5 | 0.5 | 0.5 |
| NSP14-110| 27 | 19 | 128 | 64  | 32  | 64  | 16  | 0.5 | 0.5 | 0.5 |
| NSP14-149| 27 | 19 | 64  | 8   | 64  | 32  | 64  | 16  | 0.5 | 0.5 |
| NSP14-150| 27 | 19 | 128 | 64  | 32  | 64  | 16  | 0.5 | 0.5 | 0.5 |
| NSP14-161| 27 | 19 | 32  | 8   | 64  | 32  | 32  | 8   | 0.5 | 0.5 |
| NSP14-259| 27 | 19 | 64  | 16  | 128 | 32  | 64  | 16  | 0.5 | 0.5 |
| NSP15-73 | 27 | 19 | 32  | 8   | 64  | 32  | 64  | 16  | 0.5 | 0.5 |
| NSP15-236| 27 | 19 | 128 | 32  | 64  | 128 | 0.5 | 0.5 | 0.5 |
| NSP15-531| 27 | 19 | 128 | 32  | 64  | 128 | 0.5 | 0.5 | 0.5 |
| NSP15-584| 27 | 19 | 64  | 8   | 64  | 32  | 64  | 16  | 0.5 | 0.5 |
| NSP15-635| 27 | 19 | 128 | 32  | 64  | 128 | 0.5 | 0.5 | 0.5 |
| NSP16-102| 27 | 19 | 128 | 32  | 64  | 128 | 0.5 | 0.5 | 0.5 |
| GBS16-40| 27 | 19  | 32  | 8   | 64  | 32  | 32  | 8   | 0.5 | 0.5 |
| S10003  | 529| 19  | 64  | 8   | 64  | 32  | 32  | 16  | 0.5 | 0.5 |
| S10161  | 529| 19  | 64  | 8   | 64  | 32  | 32  | 16  | 0.5 | 0.5 |
| NSP14-28| 529| 19  | 64  | 16  | 32  | 64  | 16  | 0.5 | 0.5 | 0.5 |
| NSP14-87| 529| 19  | 128 | 32  | 64  | 128 | 0.5 | 0.5 | 0.5 |
| GBS16-17| 529| 19  | 64  | 8   | 64  | 32  | 64  | 16  | 0.5 | 0.5 |
| NSP14-65| 171| 17  | 128 | 16  | 32  | 64  | 32  | 0.5 | 0.5 | 0.5 |

**Abbreviations:** ST, sequence type; CC, clonal complex; AMK, amikacin; GEN, gentamicin; KAN, kanamycin; SPT, spectinomycin; STR, streptomycin; TOB, tobramycin; CLI, clindamycin; LIN, lincomycin.
parental wild-type (WT) strains, NEM316 and COH1, respectively. Additionally, the binding of S9968 to fibrinogen was also markedly inhibited compared to that of srr1- and srr2-expressing WT strains (Fig. 1B). Moreover, we found that most of the 41 non-srr1/2 isolates exhibited reduced fibrinogen binding, with the exception of NSP14-66 of ST19, NSP14-76 and NSP14-161 of ST27, and NSP14-28 of ST529 (see Fig. S1 in the supplemental material).

The antibiotic susceptibility of non-srr1/2 isolates (n = 41) was then evaluated. All of these isolates were found to exhibit high levels of resistance to the six tested aminoglycoside antibiotics (amikacin [AMK], gentamicin [GEN], kanamycin [KAN], spectinomycin [SPT], streptomycin [STR], and tobramycin [TOB]), with MICs ranging from 8 to over 512 mg/ml (Table 3). Among them, 11 isolates showed extremely high-level resistance to clindamycin and lincomycin (LIN), with MICs ranging from 4 to >256 μg/ml. Moreover, these 11 isolates, all of which belonged to ST19, exhibited higher resistance to gentamicin, kanamycin, and tobramycin (MIC values of over 256 μg/ml) than the remaining 30 isolates.

**Whole-genome and comparative genomic analyses of non-srr1/2 strains.** To confirm the genetic organization of non-srr1/2 isolates of GBS serotype III, whole-genome analysis was performed using hybrid sequencing with the Pac-Bio and Illumina MiSeq platforms. The whole genomes of S9968 (ST19), isolated from the urine of a 48-year-old female patient with chronic renal failure and urinary tract infections, and NSP15-73 (ST27), isolated from the urine of a 50-year-old female patient with chronic renal failure and urinary tract infections, were analyzed (Table S1) to determine whether any genetic characteristics were unique to non-srr1/2 isolates. The circular chromosomes of S9968 and NSP15-73 were found to be 2,201,113 and 2,302,798 bp long, respectively, which were slightly longer than those of other sequenced serotype III strains, such as COH1 (CC17; 2,065,074 bp) and H002 (CC19; 2,147,420 bp). Additionally, the percent GC contents of S9968 (36.0%) and NSP15-73 (35.8%) were similar to those of COH1 (35.5%) and H002 (35.7%). Among the total 2,251 (S9968) and 2,348 (NSP15-73) genes, 2,149 and 2,246 were protein encoding, respectively. Additionally, the numbers of rRNAs and tRNAs in both strains were 21 and 80, respectively (49, 50). In the NSP15-73 strain, all accessory Sec2 system genes were absent, and no other gene substitutions or mutations were detected (Fig. S2). Considering the clinical importance of clindamycin and...
lincomycin in treating GBS infection in patients with allergies to penicillin, we next focused on the characteristics of non-
non-\textit{srr1}/2 isolates of GBS serotype III with aminoglycoside and lin-
cosamide resistance patterns.

Average nucleotide identity (ANI) is considered the most relevant comparative pa-
parameter used for bacterial species delineation (51). The phylogenetic analysis of S9968
compared to 21 serotype III reference strains showed that S9968 had ANI values of 99% with the other reference serotype III strains, with the exception of CNCTC8184 (98.4%) and NEM316 (98.7%), and was found to be the most closely related to H002 (99.93%) and Sag158 (99.76%), both of which belong to ST19 (Fig. 2A).

BLAST Ring Image Generator (BRIG) software was then used to create the circular
structure of the S9968 genome, which was then compared with those of H002 (STIII; 99.93%) and Sag158 (STIII; 99.76%), both of which belong to ST19 (Fig. 2A).

BLAST Ring Image Generator (BRIG) software was then used to create the circular
structure of the S9968 genome, which was then compared with those of H002 (STIII; 99.93%) and Sag158 (STIII; 99.76%), both of which belong to ST19 (Fig. 2A).

FIG 2 Genome comparison of GBS S9968 and other serotype III isolates. (A) Phylogenetic tree analysis of the S9968 strain based on ANI values obtained from whole genome sequences. The genome sequences were retrieved from the GenBank database, and ANI values were estimated using \textit{JS}pecies. The phylogenetic tree was constructed using MEGA 6.0. (B) Comparative genome visualization map of S9968 with two related genome isolates, Sag158 (GenBank accession number CP019979) and H002 (accession number CP011329). GC contents and GC skew are represented on the distance scale in the inner map. Orthologous genes found in H002 (red) and Sag158 (blue) are displayed in the outer map. The double line (green) in the map indicates the unique ORFs found in S9968.

**Genetic environment of IS\textit{1216} contigs in S9968.** Comparative genomic analysis showed that the site 4 cluster of S9968 comprised 12 open reading frames (ORFs), which contained \textit{iso(E)} for pleuromutilin-lincosamide-streptogramin A resistance, \textit{lnu(B)} for lincosamide resistance, \textit{aadK} and \textit{aadE} for streptomycin resistance, and \textit{aac-aph} for
gentamicin-kanamycin-tobramycin resistance (Fig. 3). Unlike the previously reported \textit{lnu}\textsuperscript{(B)}-carrying fragment in GBS (28, 31), which carries \textit{aadE}, \textit{spw}, and \textit{lsa}\textsuperscript{(E)}, the \textit{lnu}\textsuperscript{(B)}-carrying fragment of S9968 contains additional aminoglycoside resistance genes, \textit{aadK} and \textit{aac\textsuperscript{-aph}}\textsuperscript{(31)}. In addition, the \textit{spw} gene, which was absent from the site 4 cluster, was located in the site 3 cluster.

Basic Local Alignment Search Tool Nucleotide (BLASTN) analysis further indicated that antibiotic resistance genes (12 ORFs) in the site 4 cluster showed high similarity to those of several multidrug-resistant bacteria, including \textit{Staphylococcus} and \textit{Enterococcus}. Among them, enterococcal plasmid pKUB3007-1 carrying antibiotic resistance genes, flanked by two \textit{ISEf1} elements, shared the highest nucleotide homology with the \textit{lnu}(B)-carrying fragment of S9968 (99% maximum identity and 99.89% query coverage of the total nucleotide sequence) (53). However, it exhibited low homology with previously reported GBS \textit{lnu}(B)-\textit{lsa}(E) transposons (31).

Virulence of non-\textit{srr1/2} isolates. Srr1 and Srr2 serve as important adhesins involved in GBS invasion via the blood-brain barrier (54). In fact, deletion of \textit{srr1} or \textit{srr2} in GBS resulted in significantly lower levels of invasiveness in human brain microvascular endothelial cells (hBMECs) than those of WT GBS strains (41). Thus, to determine whether non-\textit{srr1/2} clinical isolates exhibit impaired binding to endothelial and epithelial cells, we examined if the adherence of S9968 to hBMECs and A549 cells differed compared with that of Srr1- and Srr2-expressing serotype III reference strains (NEM316 and COH1, respectively). The mutant strains deficient in \textit{srr1} or \textit{srr2} (NEM316 \textit{Δsrr1} or COH1 \textit{Δsrr2}) showed significantly diminished adherence to both hBMECs and A549 cells compared to their parental WT strains (NEM316 or COH1) (Fig. 4A and B). However, despite the defect in both the \textit{srr1} and \textit{srr2} genes, the capacity for adherence of the S9968 strain to hBMECs and A549 cells did not differ significantly from that of NEM316 and COH1.

Finally, the virulences of S9968 and Srr1- or Srr2-expressing serotype III strains (NEM316 or COH1, respectively) were compared in a mouse model of GBS meningitis. CD-1 mice (\(n = 10\) per group) were infected intravenously (i.v.) with either NEM316, COH1, or S9968, and their survival was monitored over 72 h (Fig. 4C). The results showed that 80% of the mice infected with COH1 or S9968 and 90% of the mice infected with NEM316 died within 72 h, with no significant differences among the three groups. In contrast, \textit{srr1-} or \textit{srr2-deficient isogenic mutant strains exhibited
FIG 4  Comparison of adherence rates and virulences of GBS strains. (A and B) Adherence of GBS strains, NEM316 and its isogenic mutant (Δsrr1), COH1 and its isogenic mutant (Δsrr2), and S9968, to hBMECs (A) and A549 cells (B). Data are presented as the means ± standard deviations. (C) Kaplan-Meier survival curves. CD-1 male mice were injected i.v. with GBS strain NEM316 or its isogenic mutant (Δsrr1), COH1 or its isogenic mutant (Δsrr2), or S9968 (n = 10 per group). Mouse survival was monitored for 72 h. (D to F) Bacterial loads in mouse organs. At the end of the experiment, mice were euthanized, and bacterial loads in the brain (D), lung (E), and blood (F) were assessed. *, P < 0.05; **, P < 0.01; n.s, not significant.
significantly lower virulence than their parental strains (NEM316 and COH1) or S9968. Mice were euthanized, and brain, blood, and lung tissues were collected to enumerate the bacterial loads. As shown in Fig. 4D to F, mice infected with srr1- or srr2-deficient isogenic mutants exhibited significantly lower bacterial loads in the brain, lung, and blood than those infected with the parental strains (NEM316 and COH1) or S9968.

Collectively, these findings suggest that despite the defect in Srr1 or Srr2 expression and the failure to bind fibrinogen, non-srr1/2 clinical isolates exhibited capacities for binding to brain cells and virulence comparable to those of Srr1- or Srr2-expressing isolates.

DISCUSSION

The geographic distribution of GBS serotypes varies across countries and over time. This study comprised capsular serotyping of 1,248 GBS clinical isolates collected over 4 years at the Korea University Guro Hospital, located in the southwestern region of Seoul, South Korea, which is inhabited by a diverse Asian population. Consistent with our previous report, serotype III was the most predominant serotype detected among the 10 capsular serotypes. Previously, serotype III was reported to account for 57.7% of invasive infections in neonates, 84.3% of infections in geriatric adults (55), and 21 to 28% of infections in pregnant women (56).

Although the cause of this increased invasiveness associated with serotype III GBS compared to other serotypes has not been fully elucidated, many clinical studies suggest that the lower level of production of CPS-specific antibodies during GBS infections with serotype III may be partially responsible. For example, neonatal infections with serotype III are likely associated with poor maternal transfer of serotype III CPS-specific IgG through the placenta, compared to other serotypes. Resistance to various antibiotics caused by the overprescription of antibiotics is considered another factor contributing to the climbing number of GBS infections in both neonates and adults (57). Among the 1,248 clinical isolates examined in the current study, we observed a pattern of high lincosamide resistance in serotype III. Further genomic analysis revealed that some serotype III isolates acquired more than two IS1216 elements encoded by several antibiotic resistance genes. The first IS1216 element, located in the site 3 cluster, carried only aminoglycoside resistance genes, while the second IS1216 element, located in the site 4 locus, carried both aminoglycoside and lincosamide resistance genes.

IS1216 is highly associated with several resistance genes in Enterococcus (58), Staphylococcus (58), and Streptococcus (59) species. ISEnder (https://isfinder.biotoul.fr) analysis showed that the IS1216-flanked genes identified in this study (designated IS1216-G1 and -G2 [808 bp]) shared 99% homology with IS1216E (ISEfa14; IS51Y) from Enterococcus faecium CH19 (GenBank accession number U49512) (60). Furthermore, this IS1216 element comprised 226-amino-acid (aa) transposases (Tnps) with a DDE motif for strand cleavage and rejoining as well as 24 bp of a left inverted repeat (LIR) (5′-GGT TCT GTT GCA AAG TTT TAA ATC TAC TAT CAA ATA AGG TAG AAT AG-3′) and a right inverted repeat (RIR) (5′-GGT TCT GTT GCA AAG TTT TAA ATA AAG ATC TCT ACG GTA TCT AT-3′). Although IS1216 transposases carrying lincosamide resistance genes have been previously reported in GBS (28), this is the first study to report the presence of IS1216 carrying two types of antibiotic resistance genes that are highly homologous to a portion of the E. faecalis plasmid pKUB3007-1.

IS1216 found in the site 4 cluster carried multiresistance genes, including lsa(E) and lnu(B) for lincosamide resistance and aadK, aacA-aphD, and aadE for aminoglycoside resistance. Although lincosamides such as clindamycin are recommended alternatives for pregnant women and patients who are allergic to β-lactams (16), resistance to this class of drugs has been reported in GBS clinical isolates since the 1990s, which has been shown to be caused primarily by the lnu(B) gene alone or together with lsa (31, 61). Similarly, combination treatment with a β-lactam and an aminoglycoside is commonly administered for at least the first 2 weeks of infective endocarditis (62) and
Transposable elements may alter gene expression via insertion within the coding region or the promoter region to enhance or reduce host virulence. For instance, ISFao4 of *E. faecalis* disrupts the *ddl* gene encoding the housekeeping D-alanine-D-ala-nine ligase, the absence of which results in reduced glycopeptidase resistance in *E. faecalis* (64). In the current study, non-srr1/2 clinical isolates showed the transposition of IS1216 in the accessory Sec system exporting LPxTG-anchoring glycoproteins (Srr1 or Srr2). Due to the insertion of IS1216, srr1 was completely deleted in 11 non-srr1/2 isolates.

The expression of Srr1 or Srr2 promotes GBS attachment to human brain endothelial cells via interaction with the fibrinogen Aα chain (48). Previous in vivo studies with targeted knockdown of the srr1 or srr2 gene have shown that srr1 or srr2 deficiency in GBS results in reduced virulence and colonization compared to those of parental WT strains (41). Similarly, the S9968 strain exhibited significantly lower binding of immobilized human fibrinogen than srr1- or srr2-expressing strains (NEM316 or COH1, respectively); however, its binding of endothelial and epithelial cells was comparable to that of the Srr1- and Srr2-expressing strains. Additionally, the virulence of S9968 did not differ significantly from that of Srr1- or Srr2-expressing strains in a murine model of invasive GBS infection. Comparative analysis of its genome with that of NEM316 or its closely related strain H002 revealed additional LPxTG motif-containing proteins, antigen I/II and BspA, in the site 2 gene cluster of S9968. Although the involvement of these proteins in GBS pathogenesis was not investigated in the current study, previous studies have reported that BspA and BspC are critical adhesins in GBS, which interact with the gp340 protein on human epithelial cells and the host cytoskeleton component vimentin, thereby contributing to GBS meningitis pathogenesis (65, 66). Thus, it is hypothesized that the loss of Srr1 or Srr2 in S9968, and the resulting decrease in fibrinogen binding, might be compensated by the acquisition of other cell wall-anchoring proteins, such as the BspA isotype. In fact, four isolates (NSP14-66, NSP14-76, NSP14-161, and NSP14-28) showed fibrinogen binding activity similar to or higher than that of Srr1- or Srr2-expressing serotype III strains (NEM316 or COH1). Thus, further investigation is required to define the pathogenesis of non-srr1/2 isolates as well as effective therapeutic strategies.

The results presented in this study describe IS1216 carrying lincosamide and aminoglycoside resistance genes in GBS, which might be acquired from other common multidrug-resistant bacteria such as *Enterococcus* spp. or *Staphylococcus* spp. Since all GBS clinical isolates have been reported to express either Srr1 or Srr2 protein on their cell wall, they have been considered potential vaccine candidates (43). However, this study reports the presence of GBS clinical isolates that do not express Srr1/2 following the insertion of IS1216. Thus, new strategies to develop a versatile GBS protein-based vaccine are warranted. In addition, considering the high level of resistance to lincosamide in GBS, alternative antibiotic agents should be considered for patients who are allergic to β-lactam antibiotics. Collectively, the results of this study provide important genomic evidence related to antibiotic resistance in clinical GBS isolates, which could facilitate the development of more effective treatment options.

**MATERIALS AND METHODS**

**Chemical reagents.** All chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise indicated.

**Bacterial strains.** The study was approved by the Korea University Guro Hospital (KUGH IRB number 2016GR0265). All clinical isolates (n = 1,248) were collected between 2013 and 2016 at the Korea University Guro Hospital (Seoul, South Korea), and all non-srr1/2 clinical isolates used in this study are listed in Table S1 in the supplemental material. GBS reference strains and their Srr-deficient isogenic mutants, NEM316, NEM316 Δsrr1, COH1, and COH1 Δsrr2, were kindly provided by Paul Sullivan (University of California, San Francisco, San Francisco, CA, USA).

**Capsular and genetic analyses of GBS isolates.** Capsular serotyping was conducted using the Strept-B-Latex kit (Statens Serum Institute, Copenhagen, Denmark) and a multiplex PCR assay (Table S3) as described previously (67, 68). The gene cluster flanked by two IS1216 elements was detected by PCR.
specific for the targeted region from pol to aadE (Fig. 3 and Fig. S3). The srr1 and srr2 genes were also detected by PCR using specific primers. All primers are listed in Table S4.

**Multilocus sequencing typing.** GBS multilocus sequence typing (MLST) was performed as described previously (69). Seven housekeeping genes (adhP, pheS, atr, glnA, sdaA, glcK, and rlt) were amplified and sequenced using MLST primer sets (Table S5), and PCR cycles were as follows: 1 cycle at 95°C for 5 min; 30 cycles of 95°C for 20 s, 56.2°C for 20 s, and 72°C for 1.5 min; and 1 cycle of 72°C for 5 min. The identified alleles were submitted to the S. agalactiae MLST database (http://pubmlst.org/sagalactiae/) for the assignment of sequence types (STs). In addition, each ST sharing six of the seven MLST loci with another ST in the group was clustered into a CC as described previously (70).

**Antimicrobial susceptibility testing.** The broth microdilution test was used to determine the antimicrobial susceptibilities of GBS non-srr1/2 clinical isolates to amikacin (AMK), gentamicin (GEN), kanamycin (KAN), spectinomycin (SPT), streptomycin (STR), tobramycin (TOB), clindamycin (CLI), and lincomycin (LIN) as described previously (71, 72). Briefly, GBS was inoculated in Todd-Hewitt broth supplemented with yeast extract (THY) and incubated overnight at 37°C. The culture of GBS grown overnight was diluted to an optical density at 600 nm (OD600) of 0.05 to 0.06, and 100 ml of PBS containing 5 x 10^7 CFU of GBS (NEM316, NEM316 Δsrr1, COH1, COH1 Δsrr2, or S9968) was sequenced using PacBio single-molecule sequencers (Pacific Biosciences, Menlo Park, CA, USA), performed by Macrogen Inc. (Seoul, South Korea). De novo assembly was implemented using Hierarchical Genome Assembly Process version 3 (HGAP3). The genome annotations were performed using the PROKKA pipeline (v1.13), and gene functions were identified using eggNOG (74, 75). The GenBank accession number for the genomic sequence of the GBS strain S9968 is SAMN15246708. Comparative genomic analysis was performed by analyzing ANI for nucleotide-level comparisons with 21 serotype III strains retrieved from the NCBI GenBank database (Table S6) (51). The phylogenetic tree of 22 GBS strains, 21 serotype III reference strains, and the S9968 clinical isolate was constructed using MEGA 6.0 based on the ANI values (52). Genome-wide visualization of coding sequence identities between S9968 and other genomes of serotype III strains was performed using BRIG.

**GBS adherence assay.** Human brain microvascular endothelial cells (hBMECs; Lonza, Basel, Switzerland) and human alveolar epithelial cells (A549; ATCC, Manassas, VA, USA) were cultured in RPMI 1640 medium with 10% heat-inactivated fetal bovine serum (FBS), 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25% Triton X-100 after a 30-min incubation at 37°C (76). The lysates were serially diluted and divided into 100 µl of PBS containing 5 x 10^7 CFU of GBS (NEM316, NEM316 Δsrr1, COH1, COH1 Δsrr2, or S9968). Mouse model of hematogenous GBS meningitis was described previously (41). Groups (n = 10 per group) of outbred 6-week-old male CD-1 mice ( OrientBio, Suwon, South Korea) were injected via the tail vein with 100 µl of PBS containing 5 x 10^7 CFU of GBS (NEM316, NEM316 Δsrr1, COH1, COH1 Δsrr2, or S9968). Mouse survival was monitored for 72 h. At the endpoint of the experiment, the remaining mice were euthanized, and blood and brain tissues were collected. The tissues were homogenized, and the blood as well as the brain and lung homogenates were plated on blood agar for the enumeration of bacterial CFU.

**Statistics analysis.** Differences in the bacterial strains in the in vitro assays were evaluated using unpaired two-tailed Student’s t test. The survival of mice was determined using Kaplan-Meier survival analysis; data were representative of results from three independent experiments and expressed as the means ± standard deviations using GraphPad Prism version 6.0 (GraphPad Software Inc., La Jolla, CA, USA). A P value of <0.05 was considered statistically significant.

**SUPPLEMENTAL MATERIAL**

Supplemental material is available online only.

**FIG S1, TIF file, 1.2 MB.**
REFERENCES

1. Falagas ME, Rosmarakis ES, Avramopoulos I, Valakis N. 2006. Streptococcus agalactiae infections in non-pregnant adults: single center experience of a growing clinical problem. Med Sci Monit 12:CR447–CR451.

2. Verani JR, Schrag SJ. 2010. Group B streptococcal disease in infants: progress in prevention and continued challenges. Perinatol 37:375–392. https://doi.org/10.1016/j.clp.2010.02.002.

3. Sunkara B, Bheemreddy S, Lorber B, Lephart PR, Hayakawa K, Sobel JD, Kaye KS, Marchaim D. 2012. Group B Streptococcus infections in non-pregnant adults: the role of immunosuppression. Int J Infect Dis 16:e169–e186. https://doi.org/10.1016/j.ijid.2011.11.008.

4. Centers for Disease Control and Prevention. 2016. Group B Streptococcus (GBS). 2016. Centers for Disease Control and Prevention, Atlanta, GA. www.cdc.gov/groupbstrep/index.html. Accessed 1 November 2017.

5. Song JY, Lim JH, Lim S, Yong Z, Seo HS. 2018. Progress toward a group B streptococcal vaccine. Hum Vaccin Immunother 14:2669–2681. https://doi.org/10.1080/21645515.2018.1493326.

6. Brzychczy-Wloch M, Gosiewski T, Bulanda M. 2014. Multilocus sequence typing and comparative genomic analysis of an emerging human pathogen, Streptococcus agalactiae. J Gen Virol 95:12391–12399. https://doi.org/10.1099/jgv.0.077113-0.

7. Davies HD, Jones N, Whittam TS, Elsayed S, Bisharat N, Baker CJ. 2004. Multilocus sequence typing of serotype III group B Streptococcus and correlation with pathogenic potential. J Infect Dis 189:1097–1102. https://doi.org/10.1086/382087.

8. Tettelin H, Masignani V, Cieslewicz MJ, Eisen JA, Peterson S, Wessels MR, Paulsen IT, Nelson KE, Margarit I, Read TD, Maddoff LC, Wolf AM, Beanan MJ, Brinkac LM, Daugherty SC, DeBoy RT, Durkin AS, Kolonay JF, Madupu R, Lewis MR, Rudun D, Fedorova NB, Scanlan D, Khouri H, Mulligan S, Carty HA, Cline RT, Van Aken SE, Gill J, Scarshelli M, Mora M, Iacobini ET, Telford JL, Kaper DL, Grandi G, Fraser CM. 2004. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, Streptococcus agalactiae. Proc Natl Acad Sci U S A 101:9368–9373. https://doi.org/10.1073/pnas.0406871101.

9. Wang X, Cao X, Li S, Ou Q, Lin D, Yao Z, Chen S, Wu C, Wen G, Ye X. 2018. Phenotypic and molecular characterization of Streptococcus agalactiae colonized in Chinese pregnant women: predominance of ST19/III and ST17/III. Res Microbiol 169:101–107. https://doi.org/10.1016/j.resmic.2017.12.004.

10. Lesieur A, Jassir F, Paul P, To KN, Carreras-Abad C, Seale AC, Jauneikate E, Madhi SA, Russell NJ, Hall J, Madrid L, Bassat Q, Kwatra G, Le Doare K, Lawn JE. 2020. Systematic review of group B streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates. Vaccine 38:6682–6694. https://doi.org/10.1016/j.vaccine.2020.08.052.

11. Yao Z, Jiayin W, Xinyi Z, Ling C, Mingyuan H, Simin M, Yayin L, Xinzhu L, Chao C. 2020. Identification of group B Streptococcus serotypes and genotypes in late pregnant women and neonates that are associated with neonatal early-onset infection in a South China population. Front Pediatr 8:265. https://doi.org/10.3389/fped.2020.00265.

12. Assefa S, Desta K, Lema T. 2018. Group B streptococcal vaginal colonization and drug susceptibility pattern among pregnant women attending in selected public antenatal care centers in Addis Ababa. BMC Pregnancy Childbirth 18:135. https://doi.org/10.1186/s12884-018-1791-4.

13. Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). 2010. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep 59:1–36.

14. Kasahara K, Baltus AJ, Lee SH, Edelstein MA, Edelstein PH. 2010. Prevalence of non-penicillin-susceptible group B streptococci in Philadelphia and specificity of penicillin resistance screening methods. J Clin Microbiol 48:1468–1469. https://doi.org/10.1128/JCM.02296-09.

15. Kimura K, Suzuki S, Wachino J, Kurokawa H, Yamanaka K, Shibata N, Nagano N, Kato H, Shibayama K, Arakawa Y. 2008. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 52:2890–2897. https://doi.org/10.1128/AAC.00185-08.

16. Critchfield AS, Liewsen SP, Baker CA, Matteson KA. 2011. Group B Streptococcus prophylaxis in patients who report a penicillin allergy: a follow-up study. Am J Obstet Gynecol 204:150.e1–150.e8. https://doi.org/10.1016/j.ajog.2010.08.063.

17. Le T, Bayer AS. 2003. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 36:615–621. https://doi.org/10.1086/376661.

18. Skoff TH, Farley MM, Pettit S, Craig AS, Schaffner W, Ginsman H, Harrison LH, Lynfield R, Mohle-Boetani J, Zansky S, Albanese BA, Stefonek K, Zell ER, Jackson D, Thompson T, Schrag SJ. 2009. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 49:85–92. https://doi.org/10.1086/599369.

19. Song Y, Cho EY, Choi EH, Lee HJ, Lee H. 2015. Clinical significance of serotype V among infants with invasive group B streptococcal infections in South Korea. Int J Infect Dis 38:136–140. https://doi.org/10.1016/j.ijid.2015.05.017.

20. Lu B, Chen X, Wang J, Wang D, Zeng J, Li Y, Li D, Zhu F, Cui Y, Huang L. 2016. Molecular characteristics and antimicrobial resistance in invasive and noninvasive group B Streptococcus between 2008 and 2015 in China. Diagn Microbiol Infect Dis 86:351–357. https://doi.org/10.1016/j.diagmicrobio.2016.08.023.
isolates causing disease in infants and colonizing maternal-newborn dyads. PLoS One 6:e17861. https://doi.org/10.1371/journal.pone.0017861.

56. Russell NJ, Seale AC, O’Driscoll M, O’Sullivan C, Bianchi-Jassir F, Gonzalez-Guariun J, Lawne JE, Baker CJ, Bartlett L, Cutland C, Gravett MG, Heath PT, Le Doare K, Madhi SA, Rubens CE, Schrag S, Sobarjo-Ter Meulen A, Vekemans J, Saha SK, Ip M, GBS Maternal Colonization Investigator Group. 2017. Maternal colonization with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis 65:S100–S111. https://doi.org/10.1093/cid/cix658.

57. Da Cunha V, Davies MR, Douarre P-E, Rosinski-Chupin I, Margarit I, Spinali S, Perkins T, Lechat P, Dmytruk N, Sauvage E, Ma L, Romi B, Tichit M, Lopez-Sanchez M-J, Des-corps-Declere S, Souche E, Buchriese C, Trieu-Cuot P, Moszer I, Clermont D, Maione D, Bouchier C, McMillan DJ, Parkhill J, Telford JL, Dougan G, Walker MJ, DEVANI Consortium, Holden MG, Poyart C, Glaser P. 2014. Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline. Nat Commun 5:4544. https://doi.org/10.1038/ncomms5544.

58. Liu Y, Wang Y, Wu C, Shen Z, Schwarz S, Xu XD, Daire L, Zhang W, Zhang Q, Shen J. 2012. First report of the multidrug resistance gene cfr in Enterococcus faecalis of animal origin. Antimicrob Agents Chemother 56:1650–1654. https://doi.org/10.1128/AAC.00991-11.

59. Ciric L, Brouwer MS, Mullany P, Roberts AP. 2014. Minocycline resistance in an oral Streptococcus infantis isolate is encoded by tet(S) on a novel small, low copy number plasmid. FEMS Microbiol Lett 353:106–115. https://doi.org/10.1111/1574-6968.12410.

60. Rice LB, Marshall SH. 1994. Insertions of IS256-like element flanking the chromosomal beta-lactamase gene of Enterococcus faecalis CX19. Antimicrob Agents Chemother 38:6693–701. https://doi.org/10.1128/AAC.38.11.6693.

61. Hawkins PA, Law CS, Metcalfe BJ, Chochua S, Jackson DM, Westblade LF, Jenns R, Beall BW, McGee L. 2017. Cross-resistance to lincosamides, streptogramin A and pleuromutilins in Enterococcus faecalis – 701. https://doi.org/10.1128/AAC.38.4.693.

62. Baddour LM. 1998. Infective endocarditis caused by beta-hemolytic strep tococci. The Infectious Diseases Society of America’s Emerging Infections Network. Clin Infect Dis 26:66–71. https://doi.org/10.1086/316266.

63. Zimmerli L. 2004. Joint pain and clubbed fingers. 62-year-old machinist. Praxis (Bern 1994) 93:1059–1061. (In German.) https://doi.org/10.1024/0369-8394.93.24.1059.

64. Depardieu F, Foucault ML, Bell J, Duboux A, Guibert M, Lavigne JP, Levast M, Courvalin P. 2009. New combinations of mutations in VanD-type vancomycin-resistant Enterococcus faecium, Enterococcus faecalis, and Enterococcus avium strains. Antimicrob Agents Chemother 53:1952–1963. https://doi.org/10.1128/AAC.01348-09.

65. Rego S, Heal TJ, Pidwill GR, Till M, Robson A, Lamont RJ, Sessions RB, Jenkinson HF, Race PR, Nobbs AH. 2016. Structural and functional analysis of cell wall-anchored polypeptide adhesin BspA in Streptococcus agalactiae. J Biol Chem 291:15985–16000. https://doi.org/10.1074/jbc.M116.726592.

66. Deng L, Spencer BL, Holmes JA, Mu R, Rego S, Weston TA, Hu Y, Sanches GF, Yoon S, Park N, Nagao PE, Jenkinson HF, Thornton JA, Seo KS, Nobbs AH, Doran KS. 2019. The group B streptococcal surface antigen I/II protein, BspC, interacts with host vimentin to promote adherence to brain endothelium and inflammation during the pathogenesis of meningitis. PLoS Pathog 15:e1007848. https://doi.org/10.1371/journal.ppat.1007848.

67. Poyart C, Tazi A, Reglier-Poupet H, Billot A, Tavares N, Raymond J, Trieu-Cuot P. 2007. Multiplex PCR assay for rapid and accurate capsular typing of group B streptococci. J Clin Microbiol 45:1985–1988. https://doi.org/10.1128/JCM.01597-07.

68. Imperi M, Pataracchia M, Alfarone G, Baldassarri L, Orfeci G, Credi R. 2010. A multiplex PCR assay for the direct identification of the capsular type (la to lX) of Streptococcus agalactiae. J Microbial Methods 80:212–214. https://doi.org/10.1016/j.mimet.2009.11.010.

69. Jones N, Bohnsack JF, Takahashi S, Oliver KA, Chan M-S, Kunst F, Glaser P, Rusniok C, Crook DWM, Harding RM, Bisharat N, Spratt BG. 2003. Multilocus sequence typing system for group B streptococci. J Clin Microbiol 41:2530–2536. https://doi.org/10.1128/JCM.41.6.2530-2536.2003.

70. Francisco AP, Bugalho M, Ramirez M, Carico JA. 2009. Global optimal eBURST analysis of multilocus typing data using a graphic matroid approach. BMC Bioinformatics 10:152. https://doi.org/10.1186/1471-2105-10-152.

71. Horsington J, Zhang Z, Bittner H, Hole K, Singanallur NB, Alexandersen S, Vosloo W. 2015. Early protection in sheep against intratypic heterologous challenge with serotype O foot-and-mouth disease virus using high-potency, emergency vaccine. Vaccine 33:422–429. https://doi.org/10.1016/j.vaccine.2014.11.043.

72. Koeth LM, Difranco-Fisher JM, McCurdy S. 2015. A reference broth micro dilution method for dalbavancin in vitro susceptibility testing of bacteria that grow aerobically. J Vis Exp 2015:53028. https://doi.org/10.3791/53028.

73. Kronvall G, Kahlmeter G, Myhre E, Galas MF. 2003. A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes. Clin Microbiol Infect 9:120–132. https://doi.org/10.1046/j.1469-4693.2003.00546.x.

74. Huerta-Cepas J, Szklarczyk D, Heller D, Hernandez-Plaza A, Forslund SK, Huerta-Cepas J, Szklarczyk D, Heller D, Hernandez-Plaza A, Forslund SK, Aloy P, van Helden P, Marcy K, Morris D, Zhou L, Zhang L, Fortuny E, et al. 2019. eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses. Nucleic Acids Res 47:D309–D314. https://doi.org/10.1093/nar/gky1085.

75. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics 30:2066–2069. https://doi.org/10.1093/bioinformatics/btu153.

76. Patras KA, Rosler B, Thoman ML, Doran KS. 2015. Characterization of host immunity during persistent vaginal colonization by group B Streptococcus. Mucosal Immunol 8:1339–1348. https://doi.org/10.1038/mi.2015.23.